secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001125345-24-000061
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024
--------------------------------------------------------------------------------

- Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.
- Cash, equivalents & securities $229.8M as of Dec 31, 2023, up from $154.3M; cash runway into 2026.
- Preliminary TAMARACK Phase 2 data for vobra duo in mCRPC expected at ASCO 2024; 177 patients enrolled.
- Initiated Phase 1 dose escalation of MGC026 (topoisomerase I inhibitor-based ADC) in advanced solid tumors.
- Received $100M from sale of TZIELD royalty interest and $50M milestone from Sanofi, recorded as $150.9M gain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/0001125345-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/mgnx-20240307.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer